stockrowCaris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) EV/FCF
As of 5 November 2026, Caris Life Sciences,�Inc. (CAI) trades at a EV/FCF of 181×. Over the past ten years it has ranged from −636× (October 2025) to 251× (October 2026); the current reading is higher than 93% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 108× | — |
| FY2024 | −4.6× | — |
| FY2023 | −4.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 211× | 464.00% |
| Jun 2026 | 37.4× | 0.26% |
| Mar 2026 | 37.3× | (65.27%) |
| Dec 2025 | 108× | — |
| 5 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| TWST Twist Bioscience Corporation compare | −77.9× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −64.5× |
| IBRX ImmunityBio, Inc. compare | −32.5× |
| SYRE Spyre Therapeutics, Inc. compare | −30.3× |
| CYTK Cytokinetics, Incorporated compare | −12.7× |
| KRYS Krystal Biotech, Inc. compare | 25.7× |
| PTGX Protagonist Therapeutics, Inc. compare | 62.4× |
| CAI Caris Life Sciences,�Inc. | 181× |
| TGTX TG Therapeutics, Inc. compare | 485× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement